Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.

mAbs - 1 Jan 2000

Han Siqi, Meng Yanchun, Tong Qing, Li Guangchao, Zhang Xunmin, Chen Yalin, Hu Shi, Zheng Lei, Tan Wenlong, Li Hui, Chen Yang, Zhang Ge, Li Bohua, Guo Yajun

Abstract excerpt

The anti-ErbB2 antibody trastuzumab has shown significant clinical benefits in ErbB2-overexpressing breast and gastric cancer, but resistance to the drug is common. Here, we investigated the antitumor activity of the combination of trastuzumab and the SRC inhibitor saracatinib in ErbB2-overexpres...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CSK Tyrosine-Protein Kinase

Share to Drug Synergism

Share to Oncogene Protein v-akt

Share to Receptor, ErbB-3

Share to src-Family Kinases

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 24492292
DOI: 10.4161/mabs.27443
PMCID: PMC3984329

Genes

SRC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24492292-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.PMID 24492292Read ↗

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.Semantic proximity Read ↗

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancerSemantic proximity Read ↗

Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistanceSemantic proximity Read ↗

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.Semantic proximity Read ↗

Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents.Semantic proximity Read ↗

Saracatinib (AZD0530) is a potent modulator of ABCB1‐mediated multidrug resistance<i>in vitro</i>and<i>in vivo</i>Semantic proximity Read ↗

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancerSemantic proximity Read ↗

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.